PMID- 9269988
OWN - NLM
STAT- MEDLINE
DCOM- 19970909
LR  - 20210103
IS  - 0008-5472 (Print)
IS  - 0008-5472 (Linking)
VI  - 57
IP  - 16
DP  - 1997 Aug 15
TI  - Characterization of prostatic epithelial cell lines derived from transgenic 
      adenocarcinoma of the mouse prostate (TRAMP) model.
PG  - 3325-30
AB  - To develop a syngeneic transplantable system to study immunotherapeutic 
      approaches for the treatment of prostate cancer, three cell lines were 
      established from a heterogeneous 32 week tumor of the transgenic adenocarcinoma 
      mouse prostate (TRAMP) model. TRAMP is a transgenic line of C57BL/6 mice 
      harboring a construct comprised of the minimal -426/+28 rat probasin promoter 
      driving prostate-specific epithelial expression of the SV40 large T antigen. 
      TRAMP males develop histological prostatic intraepithelial neoplasia by 8-12 
      weeks of age that progress to adenocarcinoma with distant metastases by 24-30 
      weeks of age. The three cell lines (TRAMP-C1, TRAMP-C2, and TRAMP-C3) express 
      cytokeratin, E-cadherin, and androgen receptor by immunohistochemical analysis 
      and do not appear to have a mutated p53. Although TRAMP-C1 and TRAMP-C2 are 
      tumorigenic when grafted into syngeneic C57BL/6 hosts, TRAMP-C3 grows readily in 
      vitro but does not form tumors. The T antigen oncoprotein is not expressed by the 
      cell lines in vitro or in vivo. The rationale for establishing multiple cell 
      lines was to isolate cells representing various stages of cellular transformation 
      and progression to androgen-independent metastatic disease that could be 
      manipulated in vitro and, in combination with the TRAMP model, provide a system 
      to investigate therapeutic interventions, such as immunotherapy prior to clinical 
      trials.
FAU - Foster, B A
AU  - Foster BA
AD  - Department of Cell Biology, Baylor College of Medicine, Houston, Texas 77030, 
      USA.
FAU - Gingrich, J R
AU  - Gingrich JR
FAU - Kwon, E D
AU  - Kwon ED
FAU - Madias, C
AU  - Madias C
FAU - Greenberg, N M
AU  - Greenberg NM
LA  - eng
GR  - CA58204/CA/NCI NIH HHS/United States
GR  - CA64851/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Cancer Res
JT  - Cancer research
JID - 2984705R
RN  - 0 (Androgen-Binding Protein)
RN  - 0 (Antigens, Viral, Tumor)
RN  - 0 (Cadherins)
RN  - 0 (Neoplasm Proteins)
RN  - 0 (RNA, Messenger)
RN  - 0 (Receptors, Androgen)
RN  - 0 (Tumor Suppressor Protein p53)
RN  - 0 (probasin)
RN  - 68238-35-7 (Keratins)
SB  - IM
MH  - Adenocarcinoma/metabolism/*pathology
MH  - Androgen-Binding Protein/metabolism
MH  - Animals
MH  - Antigens, Viral, Tumor/metabolism
MH  - Cadherins/metabolism
MH  - Disease Progression
MH  - Keratins/metabolism
MH  - Male
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - Mice, Transgenic
MH  - Neoplasm Proteins/metabolism
MH  - Prostatic Neoplasms/metabolism/*pathology
MH  - RNA, Messenger/metabolism
MH  - Receptors, Androgen/metabolism
MH  - Tumor Cells, Cultured/pathology
MH  - Tumor Stem Cell Assay
MH  - Tumor Suppressor Protein p53/metabolism
EDAT- 1997/08/15 00:00
MHDA- 1997/08/15 00:01
CRDT- 1997/08/15 00:00
PHST- 1997/08/15 00:00 [pubmed]
PHST- 1997/08/15 00:01 [medline]
PHST- 1997/08/15 00:00 [entrez]
PST - ppublish
SO  - Cancer Res. 1997 Aug 15;57(16):3325-30.